BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ixoberogene soroparvovec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ixoberogene soroparvovec\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06856577-11228@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Ixoberogene soroparvovec: Phase 3 readout est. (NCT06856577)
DESCRIPTION:Ixoberogene soroparvovec\, phase 3\, Wet Age-Related Macular De
 generation.\nStudy: Efficacy and Safety Study of Ixoberogene Soroparvovec 
 (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneratio
 n\nEstimated primary completion: 22 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06856577
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07482176-11228@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Ixoberogene soroparvovec: Phase 3 readout est. (NCT07482176)
DESCRIPTION:Ixoberogene soroparvovec\, phase 3\, Wet Age-Related Macular De
 generation.\nStudy: Efficacy and Safety Study of Ixoberogene Soroparvovec 
 (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneratio
 n (AQUARIUS)\nEstimated primary completion: 15 November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07482176
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630649-11228@assetmemo.bio
DTSTAMP:20261121T005025Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Ixoberogene soroparvovec: Phase 2 readout est. (NCT07630649)
DESCRIPTION:Ixoberogene soroparvovec\, phase 2\, Wet Age-Related Macular De
 generation.\nStudy: Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosin
 g Study in Participants With Neovascular Age-related Macular Degeneration\
 nEstimated primary completion: June 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07630649
URL:https://assetmemo.bio/drug/ixoberogene-soroparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
